tion, and in one with grade I biopsy-proven acute rejection. In one patient MMF was replaced Background. In renal transplantation the beneficial immunosuppressive effects of cyclosporin (CsA) may by CsA because of gastrointestinal intolerance. Mean serum creatinine 6 months after transplantation was be curtailed by its nephrotoxicity, specially in patients receiving a cadaveric allograft from suboptimal donors 159±59 mmol/l. Cytomegalovirus tissue invasive disease occurred in one patient (6%). At 6 months followor at risk of delayed graft function. Mycophenolate mofetil (MMF ) and antithymocyte globulin (ATG) up all patients are alive with functioning allografts.
Introduction
open single-arm pilot trial. From September 1996 to March 1997 we recruited 17 patients. They were treated with MMF 2 g p.o. preoperatively, and after trans-The introduction of cyclosporin A (CsA) more than a decade ago was an important breakthrough in organ plantation at 3 g/day; rabbit ATG i.v. at 2 mg/kg preoperatively, and 1.5 mg/kg/day the first day after transplantation. However, the beneficial immunusuppressive properties of this xenobiotic agent may be transplantation, followed by four doses of 1 mg/kg on alternate days; prednisone was given at 0.25 mg/kg/day curtailed by its acute and chronic nephrotoxicity. In renal transplantation, acute CsA nephrotoxicity in and reduced progressively to 0.1 mg/kg/day at 3 months. Primary outcomes were incidence of biopsy-ischaemic post-transplant renal failure may prolong oliguria and reduce graft survival rates [1, 2] . Although proven acute rejection, delayed graft function, opportunistic infections, graft and patient survival, and the some authors have described no deleterious effect of CsA on clinical outcomes of renal transplantation [3] , need for introduction of CsA treatment. Results. delayed graft function occurred in two cases others have documented renal allograft interstitial fibrosis associated with high cumulative doses of CsA [4] (12%). Four of 17 patients (24%) had a biopsy-proven acute rejection (2 grade I and 2 grade II ) within the and high CsA exposure has been related to the development of chronic transplant nephropathy [5] . In first 3 months after transplantation. CsA was added in two cases with grade II biopsy-proven acute rejec-heart-transplant recipients, chronic nephropathy with progressive renal function deterioration that may lead to chronic renal failure has been associated with long-graft function, and renal function as measured by serum is associated with a high incidence of delayed graft creatinine concentration during the initial 6 months after function [10, 11] , and these grafts seem to be more transplant. Safety parameters were the incidence of opportun- 
Results
acute rejection in renal transplantation [16 ] . So the association of MMF and ATG might be a nonnephrotoxic alternative to the standard anticalcineurin-Seventeen organs for this study were harvested from 14 cadaveric donors. Donor and recipient characterbased regimens. In this open, single-arm pilot trial we have studied the combination of MMF, antithymocyte istics are summarized in Tables 1 and 2 respectively.
Delayed graft function occurred in two cases (12%). globulin (ATG), and low-dose steroids to evaluate the incidence of acute rejection, the need for anticalcineu-The mean time to reach a serum creatinine ∏300 mmol/1 was 6.4 days.Twelve patients (70%) rin agents, and the incidence of opportunistic infections, in low-risk transplant recipients of a suboptimal required antihypertensive treatment. Mean arterial pressure 3 months after transplantation was graft or at risk of delayed graft function.
101 During the first 6 months after transplantation, 2 g per os preoperatively, and within the first 72 h after MMF doses were reduced in three patients, in which transplantation MMF was restarted at 3 g/day divided into CsA had already been introduced, to manage leukotwo daily doses. Rabbit ATG (Thymoglobuline, IMTIX, penia on day 39 (one case), or CMV infection in two Lyon, France) was given intravenously at 2 mg/kg preoperatively, and 1.5 mg/kg the first day after transplantation, cases on days 21 and 48. In five patients only treated followed by four doses of 1 mg/kg on alternate days. ATG with steroids and MMF, this drug was reduced because dosage modifications were made to maintain peripheral of CMV infection in three instances on days 30, 45 CD3+ cells <20%. Methylprednisolone 1 mg/kg was given and 60, and in two cases on days 26 and 120 to manage intravenously during the surgery and post-operatively the MMF adverse effects. Apart from the case already patients received intravenous methylprednisolone or oral described, in which rejection occurred after MMF dose prednisone at 0.25 mg/kg/day. Beyond the first month reduction on day 29 after transplantation, no rejection after transplantation prednisone was gradually tapered to resulted from the decrease in MMF dose in the 0.1 mg/kg/day 2 months later. remaining patients. In one patient MMF was replaced Efficacy parameters were the incidence of biopsy-proven by CsA 120 days after transplantation because of acute rejection, treatment failure (defined as introduction af CsA, graft loss, or recipient's death), incidence of delayed persistent gastrointestinal intolerance. Four patients NHBD, non-heart-beating donor; sCr, serum creatinine before organ harvesting; AH, arterial hypertension. Renal allografting with suboptimal organs has been associated with an incidence of delayed graft function animal models [18] . MMF might exert this protective effect due to the downregulation of the expression of (24%) had a CMV viraemia/syndrome, and one patient adhesion molecules [19] , which participate in the reper-(6%) a CMV tissue-invasive disease (pneumonitis). All fusion injury. these cases were resolved with ganciclovir. All these The 24% of acute rejection observed in this study is CMV infections occurred in positive/positive CMV similar to that reported in regimens using CsA. Despite donor/recipient serological combination. Four patients the reduced number of patients, the histological and (24%) had cutaneous herpes simplex virus infection. clinical severity of the rejection episodes seems to be No other opportunistic infections were documented in in accordance to that reported in immunosuppression these patients. No tumours have developed in any of protocols employing CsA and MMF [13] . All four the patients. All patients are alive with a functioning rejection episodes occurred within the first 2 months allograft.
after transplantation, without recurrent rejection episodes. Moreover, although reduction of MMF doses was necessary in several patients to manage MMF Discussion adverse effects, no late rejection episodes occurred. Thus, a maintenance immunosupressive treatment The results of this pilot study in a small number of using MMF and steroids, employed in 70% of our low-immunological-risk patients who received a subpatients, appears to be safe therapy. In its favour is optimal allograft or at risk of delayed graft function, that the mean serum creatinine values remained stable suggest that the combination of MMF, ATG, and during the 6-month follow-up period. low-dose steroids is an efficient immunosuppresssive Taking into account both the incidence of rejection regimen because it allows a rapid recovery of renal and CMV tissue-invasive disease observed in this study, function, provides a relatively low incidence of acute it appears that the immunosuppressive potency of the rejection, with an incidence of CMV tissue-invasive association of MMF, ATG, and steroids is similar to disease similar to that reported in other triple-therapy that of triple therapy combining MMF, CsA, and regimens based on azathioprine, steroids, and CsA steroids, in spite of the short course of ATG and the [14, 15] , and may avoid the use of this nephrotoxic low dose of steroids used. The high doses of MMF immunosuppressant in aproximately 70% of the recipients.
given in this study may reduce sensitization against Placebo-controled study of mycophenolate mofetil combined
